Search clinical trials for: Empagliflozin high

Total 7153 results

International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Type2 Diabetes Mellitus

India
Alexandria University

Completed

Empagliflozin as a Novel Therapy in Refractory Ascites

Ascites Hepatic

Egypt
Maastricht University
AstraZeneca

Completed

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation (MaasFlex)

Prediabetic State | Substrate Oxidation

Netherlands
Clinical Nutrition Research Centre, Singapore
National University Hospital, Singapore

Completed

Effects of Mixed Spices on Cardiometabolic Function - the PolySPice (PSP) Study (PSP)

Cardiometabolic Risk

Singapore
University Hospital Tuebingen

Completed

Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

Body Weight | PreDiabetes

Germany
Getz Pharma

Recruiting

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Diabetes Mellitus, Type 2 | NAFLD | NASH - Nonalcoholic Steatohepatitis

Pakistan
General and Teaching Hospital Celje

Completed

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients (ENDIS)

Diabetes Mellitus, Type 1 | Biomarkers | Endothelial Dysfunction | Arterial Stiffness | FMD | Incretins | Endothelial Progenitor Cells | SGLT 2 Inhibitors | Glucose Excursions | FPF

Slovenia
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
University of Erlangen-Nürnberg Medical School

Completed

Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure (ELSI)

Chronic Heart Failure

Germany
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
University Health Network, Toronto

Recruiting

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (NATRIURETIC)

Type 2 Diabetes Mellitus

Canada
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
Yonsei University

Unknown

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

Type2 Diabetes | NAFLD - Nonalcoholic Fatty Liver Disease

Korea, Republic of
Zhongshan Hospital Xiamen University

Unknown

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Diabetic Nephropathy | Type 2 Diabetes

China
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer
Kasr El Aini Hospital

Completed

Empagliflozin in Patients With Glomerulonephritis

Proteinuria | Glomerulonephritis

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Non-Alcoholic Fatty Liver Disease | Type2diabetes

Pakistan
Matthew Neal MD
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A)

Covid19

United States, Spain, Brazil, Italy
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Bio-innova Co., Ltd

Not yet recruiting

Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg (DAP-030-23)

Healthy Subjects
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease (EMPA-PRED)

Heart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
Dong Wha Pharmaceutical Co. Ltd.

Not yet recruiting

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.

DW6014

Korea, Republic of
Butler Hospital
National Institute of Mental Health (NIMH)

Completed

Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users

Substance-Related Disorders | Depression | HIV Infections

United States
AstraZeneca

Recruiting

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK (ZEAL UNLOCK)

Liver Cirrhosis

Italy, Japan, Germany, Belgium, Poland, Australia, United States, United Kingdom, Czechia, Slovakia
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Yangjin
Peking University Third Hospital

Not yet recruiting

Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

Prediabetic State | Impaired Glucose Tolerance | Impaired Fasting Glucose

China
Tanta University

Not yet recruiting

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Non Alcoholic Steatohepatitis

Egypt
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Healthy

China
McGill University Health Centre/Research Institute...

Recruiting

Empagliflozin in Acute Heart Failure (DRIP-AHF-1)

Chronic Kidney Diseases | Acute Heart Failure

Canada
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
Purdue University

Completed

Breakfast Consumption in Preschoolers: Satiety, Diet Quality and Memory

Obesity | Dietary Modification | Lack of Satiety | Memory Deficits

United States
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Rehab Werida
University of Alexandria

Recruiting

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 Diabetes | Nonalcoholic Fatty Liver Disease

Egypt
University of Alabama at Birmingham

Not yet recruiting

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Obesity | Weight Loss

United States
The University of Hong Kong

Recruiting

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) (CATCH-EM)

Type 2 Diabetes | Microvascular Coronary Artery Disease

Hong Kong
University of Reading
Wellcome Trust

Completed

Study Into Genetic Influence on Cholesterol Response to Dietary Fat (Satgene)

Cardiovascular Diseases

United Kingdom
Maastricht University Medical Center

Recruiting

Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction | Microvascular Dysfunction

Netherlands
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Kidney Disease, Chronic

United States, Spain, Korea, Republic of, Belgium, Australia, Hong Kong, India, Canada, China, Germany, Italy, Japan, Malaysia, Finland, Switzerland, Turkey, Hungary, Poland, Portugal, Philippines, Czechia, Greece, Bulgaria, Brazil, Arg... and more
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Research Institute for Complex Problems of Cardiovascular...

Completed

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions (SAFARY)

Coronary Artery Disease | Diabetes Mellitus | Percutaneous Coronary Intervention
National University of Malaysia

Unknown

Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Diabetes Mellitus | Chronic Kidney Diseases | Diabetic Retinopathy

Malaysia

Search clinical trials for: Empagliflozin high

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations